Although the muscarinic receptor family has long been a source of potentially compelling targets for small molecule drug discovery, it was difficult to achieve agonist selectivity within the family. A new class of M1 muscarinic agonists has emerged, and these compounds have been characterized as agonists that activate the receptor at an allosteric site. Members of this class of M1 agonists have been shown to be selective across the muscarinic receptors. However, upon introduction of a novel pharmacologic mechanism, it is prudent to ensure that no new off-target activities have arisen, particularly within the context of in vivo experiments. Reported here, is the in vitro and in vivo characterization of a novel M1 agonist tool compound, PPBI, and demonstrations that the primary biological effects of PPBI are mediated through M1. PPBI reverses D-amphetamine locomotor activity, but fails to do so in transgenic mice that do not express M1. PPBI also reverses a natural deficit in a rat cognition model at a level of exposure which also activates cortical circuitry. Most notably, PPBI is analgesic in a variety of rat and mouse models and the analgesic effect of PPBI is reversed by an M1-preferring antagonist and an M1-selective toxin. Finally, the pharmacokinetic/pharmacodynamic measures of PPBI are compared across multiple endpoints which highlights that activity in models of psychosis and pain require higher exposures than that required in the cognition model.
Introduction
Muscarinic agonism has been considered a potentially attractive therapeutic approach to treat diseases of the nervous system for decades (Feldberg, 1945) . The cloning and characterization of the five subtypes ushered the family into the era of modern drug discovery (Felder et al., 2000) . Efforts aimed at the M1 receptor, in particular, were pursued early, and several drug candidates were taken forward for clinical evaluation. The most advanced of these was xanomeline, an M1/M4-preferring agonist which showed some promise in treating symptomatic aspects of Alzheimer's disease (Bodick et al., 1997) and subsequently, some symptoms of schizophrenia (Shekhar et al., 2008) . However, the side effect profile of orthosteric M1 agonism limited progress. It has been suggested that the side effects engendered by xanomeline and other M1 agonist clinical candidates may have been the result of poor selectivity across the remainder of the muscarinic receptor family, and specifically unwanted activity at the M2 and M3 subtypes.
The allosteric agonist, AC-42, was introduced as an alternative mode of pharmacologically activating the M1 receptor. AC-42 enabled better selectivity across the muscarinic receptors than previous compounds because it acted as an allosteric (or ectopic) agonist (Spalding et al., 2002) . The M1 binding site for AC-42 was determined to overlap, yet to be distinct from, the orthosteric binding site for endogenous ligand, acetylcholine and orthosteric agonists like xanomeline. Other allosteric M1 agonists were subsequently reported. These built upon the AC-42 precedent and established M1 allosteric agonism as a new form of pharmacology. Examples included the AC-42 analogs, 77-LH-28-1 (Langmead et al., 2008) and AC-260584 (Li et al., 2007) . Also, TBPB was described as a newer generation M1 allosteric agonist and characterized as antipsychotic in an animal model (Jones et al., 2008) .
The evolution of M1 allosteric agonist pharmacology was challenged to demonstrate that the in vivo actions of these compounds are mediated exclusively through M1. AC-42 and its analogs were reported to have significant affinity as D2 antagonists (Heinrich et al., 2009 ). However, the later generation M1 allosteric agonist, TBPB was reported to have no effect on [ 18 F]fallypride binding potential in vivo at concentrations that partially reversed amphetamine-induced locomotor activity (LMA) (Jones et al., 2008) .
The observation that AC-42 and its analogs are selective within the muscarinic family, yet inhibit a relatively unrelated receptor, can be interpreted as a general cautionary reminder about pioneering unexplored pharmacological sites-of-action. Broad panel screening of isolated receptors is customarily used to establish selectivity, but this tactic may be insufficient when a new pharmacological approach is being established. In short, it is possible that a novel agonist for the M1 receptor may have unanticipated biological consequences at a site that is presently uncharacterized. For example, even though the orthosteric agonist, xanomeline was initially assumed to be devoid of non-muscarinic receptor affinity (Shannon et al., 1994) , it was later reported to possess substantial functional affinity for some serotonin receptor subtypes (Watson et al., 1998) . Furthermore, it can be assumed that commercial receptor panels do not represent the full range of biologically meaningful points of pharmacologic interaction, particularly when biological selectivity is considered within the context of a whole animal (Bantscheff et al., 2007) .
With this general caveat in mind, we set out to test whether the biological effects of a novel M1 agonist were indeed mediated through the M1 receptor. We introduce and characterize the M1 agonist, Ethyl 3-[4-(6-fluoro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]pyrrolidine-1-carboxylate (or Pyrrolidyl Piperidyl BenzImidazolinone or PPBI), and demonstrate that several in vivo effects of PPBI are dependent on functional M1 receptors using genetic and pharmacologic means. In particular, we profile the in vivo activity of this new tool compound in multiple pain models and compare the compound exposure requirements of the models.
Material and methods

in vitro pharmacology
2.1.1. Cell culture CHO cells stably transfected with human M1 to M5, rat M1, and mouse M1 receptors, were cultured in Complete Medium (Dulbecco's Mod. of Eagle Medium/Ham's F12 50/50 Mix, glutamine 2 mM, Fetal Bovine Serum 10%) supplemented with Neomycin (G418 Sulfate, 600 mg/ml), and maintained at 37 C in a CO 2 incubator.
Intracellular calcium mobilization
CHO cells stably expressing muscarinic receptors subtypes 1, 3 and 5, were diluted at a density of 8000 cells/50ml/well in Complete Medium in a 384 well plate. Following an overnight incubation, Complete Medium was removed and replaced with 25ml/well of Assay Buffer (1X HBSS without Calcium and Magnesium, 20 mM Hepes, 2.5 mM Probenecid; pH 7.4), supplemented with 2 mM FLUO4-AM and 0.02% Pluronic acid. Plates were then incubated for 1 h at 37 C, 5% CO 2 , followed by a washing step with Assay Buffer leaving 25 mL per well. The plate was then transferred onto a FLIPR, and the agonist was applied to the cells. The fluorescence response, as an indicator of changes in intracellular calcium concentration triggered by agonist stimulation, was recorded with excitation wavelength at 488 nm and emission wavelength at 510 nm, and the data were analyzed by FLIPR software. The 384-well drug plates were prepared in Assay Buffer (3X concentration, 3-fold serial dilutions for 10-points dose-response curves).
Dynamic mass redistribution (EPIC from corning)
CHO cells stably expressing the human M2 an M4 receptors were diluted at a density of 7500 cells/40ml/well in Complete Medium in 384-well fibronectin-coated EPIC plates. Following an overnight incubation step, Complete Medium was replaced through a wash cycle with 30ml/well of EPIC Assay Buffer (HBSS 1X, 20 mM Hepes, 1.3 mM CaCl 2 , 0.5 mM MgCl 2 , pH 7.4). After incubating at room temperature for 60 min, a baseline was established, after which agonist was added and results recorded for 30 min. The 384-well drug plates were prepared in EPIC Assay Buffer (4X concentration, 2e3-fold serial dilutions for 12-points dose-response curves). The EPIC protocol was set for a single addition and the data were analyzed by EPIC software.
Analysis
Concentrationeresponse curves were generated by fitting data to a 4-parameter logistic equation using Prism 4.0 software (GraphPad, San Diego, CA). Maximal efficacy (E max ) is reported as % normalized to the response to acetylcholine.
in vivo pharmacology
Animals
The local AstraZeneca Animal Care Committees approved all experimental protocols. Experiments were carried out according to AAALAC (Association for the Assessment and Accreditation of Laboratory Animal Care). Analgesia experiments were conducted in Montreal and carried out according to CCAC (Canadian Council on Animal Care) guidelines. For locomotor assays, subjects were male C57Bl/6 mice or M1 gene deficient (M1-KO) mice on a C57Bl/6 background, all obtained from the laboratory of Jürgen Wess (Miyakawa et al., 2001) . M1 (wt/wt) and M1(À/À) were littermates. Mice weighed approximately 22e30 g at the time of the experiment. They were maintained on a 12/12 h light/dark cycle and had free access to food and water. Mice were individually housed and cage cards marked with animal ID numbers and drug treatment. Analgesia experiments were conducted in male C57BL/6N mice (19e20 g; Charles River, St-Constant) and Sprague-Dawley rats (125e200 g, Charles River, St. Constant, Canada and Harlan Inc., Indianapolis, USA). Mice (groups of 5) and rats (groups of 7e8) were housed in a temperature controlled environment (22 ± 1.5 C, 30e80% relative humidity, 12/12 h light/dark cycle) and were acclimatized in the animal facility for at least 3 days prior to use. Experiments were performed during the light phase of the cycle. Animals had food (Harlan Teklad, Montreal, Canada) and water ad libitum. The number of animals used was the minimum necessary to achieve an 80% statistical power at a 30% reversal of hyperalgesia. For Novel Object Recognition, Male Sprague Dawley rats from Taconics, Denmark, 9 weeks old at arrival were used. These were fed expanded rodent chew RM1(E), (code 801002, from SDS, Essex, England) and tap water ad libitum. In all cases, the experimenter was blind to the treatment the animals received, all experimental animals were randomized with regard to treatment, and both treatment and control experiments were performed on the same days.
2.2.2. Blockade of D-amphetamine-induced locomotor activity (damp LMA) in wild-type or m1-KO mice LMA studies were conducted in open field activity chambers obtained from Med Associates (Georgia, Vermont, USA) interfaced to a personal computer. Activity monitoring was carried out using Open Field Activity Software (Med Associates). The ability of PPBI to block LMA in mice was assessed using a habituation and d-amp challenge protocol. Briefly, mice subjected to a habituation period of 60 min followed by an injection of d-amp (3 mg/kg s.c.) followed by a second 60 min test. A dose range-finding experiment with PPBI was conducted in C57/B6 wild type mice using 30 and 100 mmol/kg po (and also 0.1 mg/kg haloperidol as a positive control). In the M1-KO experiment, PPBI 60 mmol/kg p.o. was selected as a moderate dose. In all experiments, PPBI or vehicle were administered immediately before the beginning of the habituation period (i.e., 60 min before d-amp) while 0.1 mg/kg s.c. haloperidol was administered 15 min before d-amp. On the day of the study, 10 mice per group were randomly assigned to the different treatment groups and treatment groups were balanced across activity chambers. Drug/dose treatment and geneotype (wt or M1 À/À) were independent variables and distance traveled was the dependent variable.
LMA study statistical analysis
Dose-response was analyzed using a one-way ANOVA followed by a Tukey test for post-hoc comparisons. For the drug x genotype interaction, a two-way ANOVA was used followed by a one-way ANOVA for each genotype, wild-type and M1(À/À) mice, to determine if PPBI or haloperidol reduced D-amphetamine LMA. A value of P < 0.05 was used tests of significance.
Induction and assessment of the mouse Freund's complete adjuvant (FCA) model of inflammatory pain
The FCA method used in the experiments described has been previously reported (Gilbert et al., 2013) . Under isoflurane anesthesia, 20 ml of FCA (Sigma) was injected subcutaneously 3 cm from the tip of the tail. Tails were marked 5 cm from the tip with a permanent marker where the extension of inflammation was visible. All experiments were conducted 24 h after FCA administration. Naïve mice were used as controls. Heat hyperalgesia was assessed using the hot water tail immersion test. Mice were wrapped in a paper towel with the tail protruding. With the mouse held horizontally over a water bath, the tail was dipped to the 5 cm mark. The tail withdrawal latency (TWL) from the 46 C water bath was recorded, the assay cut-off was set at 60 s. The following behaviors were considered tail withdrawals: (1) tail curves ventrally and suddenly lashes towards the surface of the water with a whiplike movement; (2) tail wiggles from side to side several times with increasing urgency; (3) tail slowly curves ventrally either stopping in mid-curve or coiling up towards the surface without completing a flick. Mechanical hyperalgesia to the tail was assessed using the Randall Selitto apparatus. With the tail protruding, the mouse is held horizontally and the tail is introduced between plinth and pusher of the apparatus to target an area at 5 cm away from the tip of the tail. The force applied to the tail increases at a constant rate until the mouse removes its tail or attempts to remove its tail. The raw value is recorded off the scale, transformed to yield a value expressed in g/cm 2 . A cut off of 570 g/cm 2 is used. Both heat and mechanical hyperalgesia are assessed on the same mice with heat hyperalgesia readout being 10 min prior to mechanical hyperalgesia assessment.
Induction and assessment of the mouse oxaliplatin model of neuropathic pain
Oxaliplatin (3 mg/kg) or vehicle (distilled water) was administered intraperitoneally in a volume of 10 ml/kg. Mice were injected twice weekly for 4.5 weeks (9 injections) for a total cumulative dose of 27 mg/kg. Animals were closely monitored for allergic reactions and side effects for the entire treatment phase (4.5 weeks). All experiments were conducted between days 20e120 after the last oxaliplatin administration. Naïve mice were used as controls. In order to assess cold allodynia, mice were placed individually in Plexiglas cylinders on a clean wire mesh rack and allowed to acclimate for 20 min before testing. The duration of nocifensive behaviors (lifting, slapping, flinching or licking) over 60 s following the application of 25 ml of acetone onto the dorsolateral surface of the affected (ipsilateral) hind paw was recorded; 2 determinations were made, 10 min apart. Data represents the cumulative score (in seconds) of these two determinations. Cold allodynia was also assessed using the cool water tail immersion test. Mice were wrapped in a paper towel with the tail protruding; habituation for this manipulation is carried out the day before the experiment to minimize struggling in the paper towel. With the mouse held horizontally over a water bath, the tail was dipped to the 5 cm mark. TWL from the (13 C) water bath was recorded; the assay cutoff was set at 40 s. Behaviors mentioned above are considered tail withdrawals.
2.2.6. Induction and assessment of rat spinal nerve ligation model of neuropathic pain
As previously described in detail by Kim and Chung (1992) , under isoflurane anesthesia, an incision was made dorsal to the lumbosacral plexus. The paraspinal muscles (left side) were separated from the spinous processes, the L5 and L6 spinal nerves isolated, and tightly ligated with (4e0 silk suture) distal to the dorsal root ganglion. The incision was closed in layers, and the skin was sealed with tissue adhesive (Vetbond). Rats were allowed to recover and then placed in cages with soft bedding. All experiments were conducted between postoperative days 7e25. Naive rats were used as controls.
In order to assess the degree of heat hyperalgesia, the rats were placed individually in Plexiglas boxes on the glass surface (maintained at 30 C) of the paw thermal stimulator system (IITC Life Science, Woodland Hills, CA, USA, Model 390 Series 8), and allowed to acclimate for 30 min. A thermal stimulus, in the form of a radiant heat beam was focused onto the plantar surface of the affected paw. In each test session, rats were tested twice at approximately 5 min apart. Paw withdrawal latencies (PWLs) were calculated as the mean of the two values. An assay cut off was set at 20 s.
Induction and assessment of the rat FCA model of inflammatory pain
The FCA method used in experiment has been previously reported (Martino et al., 2011) . Under isoflurane anesthesia, inflammation was induced by the single administration of 25 ml of FCA injected into the subcutaneous space of the plantar aspect of the left hind paw, in the center of the pads. Assessment of heat hyperalgesia was determined as described above. All experiments were conducted 24h after FCA administration. Naïve rats were used as controls. Mechanical hyperalgesia was assessed using the Ugo Basile analgesy meter (Ugo Basile, Comerio, Italy). Animals were gently restrained, and a steadily increasing pressure was applied to the dorsal surface of a hind paw via a probe with a dome-shaped tip (diameter of 1 mm). The pressure required to elicit paw withdrawal was determined. An assay cut off was set at 295 g. 20 min before testing at a dose of 10 nmol (10 ml/rat). Muscarinic toxin-7 (MT-7, Peptides International, MW ¼ 7472.5) or vehicle (saline) was administered i.c.v. 20 min before testing at a dose of 0.27 nmol (2 mg, 10 ml/rat).
2.2.9. Collection of plasma and brain tissue, and determination of drug levels in pain studies Satellite animals were used for plasma and brain tissue collection. Under isoflurane anaesthesia, animals were subjected to nerve or soft tissue injury. At the appropriate time point, animals were injected with drug but not subjected to any nociceptive testing. Blood and brain were collected by decapitation without anaesthesia. Whole blood was transferred to heparinized tubes and centrifuged at 3000 g for 5 min. Plasma supernatant and brain were then collected and frozen (À80 C). The determination of the total plasma concentration was performed by protein precipitation, followed by reversed-phase liquid chromatography and electrospray mass spectrometry. The determination of the brain concentration was performed after homogenization and protein precipitation, followed by reversed-phase liquid chromatography and electrospray mass spectrometry.
Pain study statistical analysis
Analyses of raw in vivo data were made using one-way ANOVA or Kruskal-Wallis one-way ANOVA on ranks on raw data followed by post-hoc Holm-Sidak t-tests. The level of statistical significance was set at p 0.05. Data are presented as % efficacy calculated by [(Response dose e response vehicle ) / (response naive e response vehicle ) Â 100%] using mean ± standard error of the mean (SEM) at each point. The ED 50 is defined as the dose required to produce 50% reversal of hyperalgesia where response of naïve animals defines 100% and response of vehicle-treated animals defines 0%. The ED 50 (and EC 50 values based on measured brain concentration, see PK/PD analysis) were calculated using non-linear regression analysis in GraphPad prism (GraphPad Software Inc., San Diego, CA).
Novel object recognition (NOR)
Training day: Each rat was habituated to the experimental room 60 min before training. Thereafter, each animal was habituated to a cage (60 Â 40 Â 30 cm), which was subsequently used for only that individual animal, for 2 Â 60 min.
Test day: The rats were again habituated to the room for 60 min after which the experiment was initiated. The animals were then put in their cage for 3 min without any objects present. The animal was then removed and 2 identical objects were put into the cage. The rat was placed back into the cage and allowed to explore both objects during 3 min (T1). The animal was again removed and the two objects were changed to one identical object to that in the previous session and a new one. Three hours later, the rat was put back in the cage and allowed to explore for another 3 min. The rat was removed and the next animal was tested. PPBI, 0.2, 2 and 20 mmol/kg was dissolved in 0.9% NaCL. The compound was given p.o. 60, 150 or 300 min prior to test (5 ml/kg). All data were videotaped and analyzed after finishing the experiment, extracting total time of exploration and time exploring each object. The discrimination index was calculated as T exploration new object/T total exploration of objects. The treatments were blind to the experimenter. The objects used in the NOR were 5.0 Â 5.0 Â 7.0 cm, circular-shaped, non-transparent, black or white in color and made of metal. Two identical objects were used for habituation and two different pairs for memory testing. After each trial, the objects were thoroughly cleaned with 70% ethanol to remove odor cues.
NOR statistical analysis
Treatment groups were compared using a one-way ANOVA. In cases where the ANOVA reached statistical significance, the treatment groups were compared pairwise using Tukey's HSD tests. Statistical significance was considered at P < 0.05. Analysis was made using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA).
Pharmacological MRI
Pharmacological MRI (phMRI) experiments were performed on 250e300 g male Sprague-Dawley rats. The animals were anesthetized with 5% Isoflurane, two iv catheters were placed in left and right femoral vein for compound and contrast agent administration respectively. The anesthesia was maintained at 1.8e2% during the MRI experiment. The MRI data were acquired on a Bruker 9.4T magnet with a quadrature receive coil (Bruker, Germany) and a 72 mm resonator (Bruker, Germany). The phMRI experiments used an EPI-sequence with a matrix size 64 Â 64/FOV 30 Â 30 mm, TE ¼ 15 ms, TR ¼ 2s. The geometrical setup was 15 contiguous axial slices, slice thickness 1 mm. The USPIO Resovist™ was used as a contrast agent, to sensitize the phMRI data to changes in cerebral blood volume. The animals were administered 0.7 ml/kg Resovist™ 5 min after the phMRI experiment started. A base line of 10 min after the contrast agent administration was acquired before the PPBI compound was given. The hemodynamic response was calculated from the equation given by Mandeville (Mandeville et al., 1998) . To quantify the activation, an area-under-the-curve for the HDR time-course for each animal, in a specific region, is calculated. This is defined as the total hemodynamic response (tHDR) in that region.
2.3. Pharmacokinetic/pharmacodynamic (PK/PD) analysis 2.3.1. Permeability and active transport studies Bi-directional transport was measured across the MDR1-MDCK cell monolayer stably expressing the human multidrug-resistant (MDR1) protein, P-glycoprotein (P-gp). Compounds were dosed at 1 mM to the apical compartment to determine transport from apical (A) to basolateral (B) and to the basolateral compartment to determine transport from B to A. Samples from both sides of monolayer were taken at 1 h. Permeability and active transport parameters are defined as follows:
Where; Vr ¼ volume of receiver cm 3 , Cr ¼ concentration in receiver at 60 min, Co ¼ initial concentration in donor, Vd ¼ volume of donor, Cd ¼ concentration in donor at 60 min, and A ¼ surface area of inserts.
Free brain hypothesis and PK/PD
The extent of CNS penetration can, in part, be described as the ratio between brain and blood (or plasma) total concentration. While the total brain to blood ratio is an important measure to assess CNS penetration of test compounds, it must be recognized that it is a combined parameter that accounts for plasma protein binding, non-specific brain tissue binding, blood brain barrier permeability, and active transport at the blood brain barrier (Alavijeh and Palmer, 2010) . For CNS targets, it is widely recognized that unbound brain levels drive pharmacodynamic effects, making accurate estimations of unbound brain concentrations critical for meaningful PK/PD assessments and in vitro/in vivo potency correlations (Alavijeh and Palmer, 2010) . All assessments of the relationship between in vivo pharmacodynamic/efficacy responses and in vitro potency at the M1 receptor were constructed as a function of estimated unbound brain levels.
In the absence of active transport at the blood-brain barrier, unbound plasma levels are a predictive surrogate for unbound brain levels for permeable compounds at pharmacokinetic steady state (Kalvass and Maurer, 2002) . PPBI proved to be a moderate Pgp substrate with a measured efflux ratio (MDR1-MDCK) of 4.1. The impact of active transport at the blood brain barrier to the CNS distribution of PPBI was confirmed with in vivo CNS exposure studies where the observed Brain/Plasma ratio was 3-fold less than that predicted, using the method from Kalvass, et. Al (Kalvass and Maurer, 2002) . To account for the impact of P-gp on unbound brain concentrations, unbound brain levels of PPBI were estimated by multiplying the total brain concentration by the calculated unbound fraction determined from an in vitro assessment of nonspecific brain binding.
Results
in vitro pharmacology
PPBI is an in vivo tool compound that was discovered through a directed, synthetic chemistry effort built upon the results of a highthroughput screen. It is a potent agonist at the cloned, expressed M1 receptors from human, rat, and mouse species with a functional EC 50 of 5, 8, and 21 nM, respectively (Table 1) . Moreover, PPBI is selective for M1 over other muscarinic receptor subtypes ( Fig. 1 and Table 2 ); it is a full agonist at M1 with a functional potency more than 10-fold than that of M4 (where it is a partial agonist) and is more than 100-fold more potent at M1 versus M2, M3 & M5. PPBI is also found to be very selective for M1 when evaluated across a standard panel of ninety-five receptors which include the dopamine D 2 receptor (Supplemental Table) . Within the broad panel, PPBI is found to be 'active' only in a rat adrenergic a 1a binding assay displaying 57% inhibition at a 10 mM concentration.
Analgesia studies
Muscarinic agonism has been proposed as a potential analgesic therapy as a supplement or monotherapy in clinical settings and in preclinical research models, although the specific receptor requirements have not been well defined (Ireson, 1969) . We evaluated PPBI in both mouse (Fig. 2a) and rat (Fig. 2b ) models of pain and found that it reverses thermal and mechanical allodynia/ hyperalgesia in a dose-dependent manner. Inflammatory hypersensitivity was induced in mice through an FCA-challenge to the tail. Responses to proximal pressure and heat were evaluated in mice treated with doses of PPBI between 6 and 60 mmol/kg (Fg. 2a).
Compound treatment dose-dependently reversed responses to pain stimuli in FCA-challenged mice. PPBI also dose-dependently reverses oxaliplatin-induced cold allodynia in mice. Mice challenged with either FCA or oxaliplatin and treated with the highest doses of PPBI displayed less sensitivity to painful stimuli than control mice, though the mice appeared otherwise normal.
In FCAechallenged rats (Fig. 2b) , PPBI is active in reversing the hyperalgesic response to heat or paw pressure. In a peripheral neuropathy rat model (i.e., spinal nerve ligation or SNL), the compound reverses the hyperalgesic responses to heat stimuli. The potency of PPBI across the various pain models is very similar, particularly when factoring in the slight differential potency of PPBI at the mouse and rat M1 receptors.
The SNL rat neuropathy model was also used to explore the pharmacologic specificity of the PPBI effect on reversing heat hyperalgesia. An intracerebroventricular (i.c.v.) injection of the M1-preferring antagonist, pirenzepine, given 40 min after oral dosing of PPBI, blocks 90% of the analgesic efficacy of PPBI (Fig. 3) . A similar reversal of 79% of the PPBI-mediated analgesia is seen with i.c.v. injection of the M1-selecitve mamba toxin, MT-7. These results suggest that the analgesic effect of PPBI requires central activation of muscarinic M1 receptors. , and M5 (diamonds) receptors were profiled using the FLIPR protocol. The Gi-coupled M2 (squares) and M4 (inverted triangles) receptors were profiled using the EPIC protocol. The mean value of one duplicate experiment for each subtype ± standard deviation is shown. All responses are normalized to acetylcholine (ACh) responses at subtype. The summary data for all experiments are presented in Table 2 .
Other behavioral studies
Agonism at muscarinic receptors has also been considered a potential symptomatic treatment approach toward schizophrenia for some time and reversal of D-amphetamine-induced LMA in rodents is considered a useful preclinical model of the hyperdopminergic state associated with schizophrenic psychosis (Shannon et al., 2000) . PPBI at a dose of 30 mmol/kg reverses Damphetamine-induced LMA in C57 mice by 50% and a 100 mmol/kg dose reverses D-amphetamine-induced LMA in C57 mice by 88% (Fig. 4a) . However, PPBI does not reverse LMA in mice that lack the M1 receptor (Fig. 4b) , suggesting that M1 activity is required for the biological effect.
M1 agonists have been pursued as a treatment for cognitive deficits for decades (Levey, 1996) . We find that PPBI is very potent in reversing a temporally-induced deficit in a rat model of cognition (Fig. 5) . Following oral doses of both 2 mmol/kg and 20 mmol/kg, PPBI rescues the deficit in NOR. No dose of PPBI tested influences overall exploration time, emphasizing the specific nature of the effect on consolidation and recall. Furthermore, cognitive enhancement is maintained for at least 5 h after dosing. The potency of PPBI in this experimental paradigm strongly implies that the effect is mediated through M1 receptor activation.
fMRI studies
Localization studies have found that M1 is the most densely expressed muscarinic receptor in the cortex (Buckley et al., 1988) . Thus, we evaluated cortex as the region-of-interest in a pharmacologic magnetic resonance imaging (fMRI) study with PPBI in rats (Fig. 6) . Intravenous bolus doses of PPBI at 2 and 20 mmol/Kg activate cortical circuitry as measured by the relative total hemodynamic response. Controlled infusion at a concentration that mimics the measured plasma level found following the minimal effective dose used in the NOR paradigm also activates the cortex. Furthermore, a combination of bolus dosing, followed by controlled infusion, demonstrates that the effect is rapidly achieved and sustained over time.
A compilation of the data allows a comparative viewing of the relative pharmacokinetic/pharmacodynamic relationships across all disease models (Fig. 7 and Table 3 ). In each case, the brain levels of free PPBI at the ED 50 (or the lowest statistically significant dose for LMA and NOR) are converted to a multiple of the in vitro EC 50 for PPBI at the respective species. In general, there is consistency across species and disease models; nearly all models require approximately 10-fold excess of free brain concentrations over the in vitro EC 50 to achieve activity in the animal model. Activity in the NOR model was observed a lower relative exposure (i.e., comparable to the EC 50 ).
Discussion
PPBI is a novel M1 agonist, selective across the muscarinic family and a panel of 95 other targets (see supplemental table) . The compound is a moderate substrate of P-glycoprotein (P-gp), so the potential for drug-drug interactions should be evaluated before progressing to clinical development. As an in vivo, preclinical tool compound, we find that PPBI is active in several animal models. PPBI reverses hyperdopaminergic LMA in wild-type mice. A dose of 30 mmol/kg PPBI produces a 50% reduction in LMA, which corresponds to a ten-fold excess of brain free-fraction (corrected for Pgp) over the in vitro mouse M1 EC 50. A dose of 100 mmol/kg PPBI expressed as mean ± SEM, n ¼ 5e16 per group, FCA 96h/heat hyperalgesia (r-FCA-hh, solid squares), FCA 96h/paw pressure (r-FCA-pp, solid circles), and SNL/heat hyperalgesia (r-SNL-hh, solid triangles). Significance measures (*p 0.05, **p < 0.01, ***p < 0.001) are based on comparisons to vehicle-treated groups using raw data as described. Fig. 3 . The analgesic effect of PPBI is reversed by both an M1-preferring antagonist and an M1-selective toxin in the rat SNL heat hyperalgesia model. Paw withdrawal latencies are expressed as mean ± SEM, n ¼ 7e8 per group. PPBI (20 mmol/kg, 4 ml/kg, p.o.) or vehicle were delivered 40 min before intracerebroventricular injection of pirenzepine (10 nmol/10 ml, 10 ml/animal), or MT-7 (0.27 nmol/10 ml, 10 ml/animal) and tested 20 min later. *p ¼ 0.05, **p ¼ 0.01 (compared to vehicle-treated group), #p < 0.05, ##p < 0.01 (compared to PPBI-treated group).
produces an 88% reduction in LMA and a free brain exposure of PPBI that exceeds the EC 50 by approximately 65-fold. At this concentration, PPBI could also engage M4 receptors. M4 activation is sufficient to reverse hypderdopaminergic LMA (Byun et al., 2014) . The selective allosteric M1 agonist, TBPB, was reported to partially reverse LMA in Sprague-Dawley rats, an animal model of hyperdopaminergia (Jones et al., 2008) . PPBI, however, does not reverse LMA in transgenic mice devoid of M1 receptors, highlighting that functional M1 receptors are necessary for the effect observed.
PPBI is antinociceptive in a broad spectrum of pain models and the analgesic properties of PPBI require central M1 activation. PPBI is dose-dependently analgesic in models of both neuropathic and inflammatory pain. The M1-preferring agonist, Xanomeline was noted to be analgesic (Martino et al., 2011) . It was concluded that supraspinal M1 activation played a major role in the analgesic effect of Xanomeline, and that supraspinal M4 activation played a minor role. In contrast, a prior study had concluded that the analgesic action of a non-selective muscarinic agonist was mediated through spinal M4 receptors (Sullivan et al., 2007) . Nearly all the analgesic action of PPBI in a SNL model of neuropathic pain can be blocked by central administration of the M1-preferring antagonist, pirenzepine. Similarly, most of the analgesic action of PPBI in this model is blocked by i.c.v. administration of the potent and selective peptide toxin, MT-7 (Olianas et al., 2000) . These observations support the conclusion that the activity of PPBI in the SNL model is dependent on activation of central M1 receptors.
The dose-response relationships for PPBI across the various pain models are all within a factor of two when the free brain exposure of PPBI is considered as a multiple of the species-specific affinity (Fig. 7) , suggesting that the central activation of M1 may be generalizable across the various models. The exposures required to achieve ED 50 in pain models are all approximately ten-fold that of the respective in vitro EC 50 . In a typical logistic function, these values would correspond to approximately 88e95% receptor activity. While it is not possible to extrapolate from the in vitro pharmacologic values and conclude that the in vitro relationship is recapitulated precisely in the animals, the relatively narrow range of exposures required to achieve median responses suggests that the activity of PPBI across the pain models has a consistent biologic basis.
The function of the cholinergic system in nociception has been reviewed in detail (Jones and Dunlop, 2007) and roles for each of the muscarinic receptors have been considered. Roles for spinal M2 receptors (Gomeza et al., 1999) , spinal M3 receptors (Honda et al., 2000) and spinal M4 receptors (Duttaroy et al., 2002; Sullivan et al., 2007) have each been proposed. An antinociceptive function of central M1 receptors has been both proposed (Bodick et al., 1997) and challenged (Sheardown et al., 1997) . We find that the M1 selective agonist PPBI displays consistent antinociceptive activity across a broad panel of pain models. Moreover, the analgesic action of PPBI can be blocked central administration of the M1-preferring antagonist (90%), pirenzepine or MT-7 (79%). PPBI-treated mice were less sensitive to painful stimuli than control mice in the majority of nociception studies. A modulatory influence of PPBI on sensory input would be consistent with this observation and although no sedation was observed at any dose, a modest sedative effect at the highest doses is possible. It is also worth noting that in the d-amp LMA assay, M1 (À/À) mice treated with 60 mmol/kg of PPBI displayed no signs of sedation.
The cortex is the richest source of M1 receptors (Levey, 1996) and activation of cortical M1 receptors may modulate the descending control that is relayed through the brainstem (Tracey and Mantyh, 2007) . Given that antagonists of PPBI were administered i.c.v., it is concluded that the effects reported here are dependent on activation of central M1 receptors. The pharmacokinetic requirements for the analgesic effects of PPBI (i.e., exposure of free compound in excess of in vitro EC 50 ) are consistent across the various pain models. The requirements observed for the LMA effect of PPBI fall within that same range. The mechanistic circuitry underlying M1-mediated LMA reversal and the analgesic effect may share common features.
PPBI is potently active in reversing a temporally-induced deficit in cognition in the rat NOR assay. Using fMRI, PPBI is found to increase cortical activity in combined bolus/infusion protocol that closely parallels the exposure profile of the lowest active dose in the NOR study and detection of cortical activation is sustained throughout the protocol. The free brain concentration of PPBI at this exposure is very close to the in vitro EC 50 at the rat M1 receptor. Intriguingly, the exposure required to realize robust cortical Table 3 .
Table 3
Relative pharmacokinetic/pharmacodynamic measures of PPBI across various disease models. PPBI plasma and brain levels were measured at the end of each of in vivo experiment. For pain models, exposure was interpolated from the ED 50 calculated from the dose-response relationship. Exposure values for LMA and NOR were calculated based on the lowest dose required to demonstrate a statistically significant result. Values were converted to a free concentration in plasma or brain based on calculated freefraction estimates. Fold exposure was determined by dividing the free concentration of PPBI in brain by the respective species in vitro EC 50 (mouse: 21 nM, rat: 8 nM). activation and robust activity in the cognition model are roughly one order of magnitude lower than those required for activity in the pain models. The NOR assay examines the effect of PPBI on the animal's tendency to perceive a familiar object as novel over time.
In contrast, all pain assays in this study (and the LMA) measure animal behavior as a consequence of a pharmacologic or surgical perturbation. It may be that NOR endpoints are more sensitive to M1 activation simply because the test animals are not disrupted by pharmacologic or surgical means. Functional M1 receptors are required for the analgesic effect of PPBI, though a level of M1 activation greater than that required the pro-cognitive effect is necessary. Nevertheless, M1 activation is concluded to be responsible for both the analgesic and pro-cognitive effects of PPBI. A relationship between cognition and pain states is known. The anterior midcingulate cortex has been proposed as an anatomical nexus of pain and cognition (Shackman et al., 2011) . A M1 agonist that activates cortical receptors may be useful for treating clinical conditions that present with both cognitive disruption and pain symptoms (e.g., cancer pain or Alzheimer's).
Conclusion
PPBI is a novel M1 agonist that is selective within the family of muscarinic receptors and across a panel of unrelated targets. It is active in several in vivo models and the in vivo activity requires the presence of functional, cortical M1 receptors. The analgesic activity of PPBI requires functional M1 receptors in brain and a 10-fold higher exposure than that required for the pro-cognitive effects of PPBI.
